Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $690.02 | 8 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $138.35 | 3 | $0 (2019) |
| Incyte Corporation | $127.94 | 1 | $0 (2022) |
| Genentech USA, Inc. | $125.00 | 1 | $0 (2021) |
| Amgen Inc. | $111.70 | 1 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $93.86 | 1 | $0 (2018) |
| AbbVie, Inc. | $93.17 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $127.94 | 1 | Incyte Corporation ($127.94) |
| 2021 | $125.00 | 1 | Genentech USA, Inc. ($125.00) |
| 2019 | $250.05 | 4 | PFIZER INC. ($138.35) |
| 2018 | $93.86 | 1 | Janssen Scientific Affairs, LLC ($93.86) |
| 2017 | $93.17 | 1 | AbbVie, Inc. ($93.17) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/25/2022 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $127.94 | General |
| Category: Dermatology | ||||||
| 11/18/2021 | Genentech USA, Inc. | Erivedge (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: BioOncology | ||||||
| 05/02/2019 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $10.81 | General |
| Category: DERMATOLOGY | ||||||
| 03/28/2019 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $116.15 | General |
| Category: DERMATOLOGY | ||||||
| 03/05/2019 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $11.39 | General |
| Category: DERMATOLOGY | ||||||
| 02/25/2019 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $111.70 | General |
| Category: Inflammation | ||||||
| 03/22/2018 | Janssen Scientific Affairs, LLC | Tremfya (Drug) | Food and Beverage | In-kind items and services | $93.86 | General |
| Category: Immunology | ||||||
| 04/27/2017 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $93.17 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 11 | 524 | 664 | $57,415 | $33,877 |
| 2021 | 17 | 1,047 | 1,438 | $117,723 | $80,581 |
| 2020 | 21 | 1,358 | 1,874 | $151,370 | $93,341 |
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 136 | 173 | $16,155 | $9,574 | 59.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 58 | 75 | $9,789 | $6,033 | 61.6% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2022 | 61 | 81 | $6,066 | $3,938 | 64.9% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 54 | 54 | $5,575 | $3,293 | 59.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 52 | 52 | $5,989 | $3,139 | 52.4% |
| 11106 | Incision biopsy, first skin growth | Office | 2022 | 22 | 22 | $3,499 | $2,361 | 67.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 33 | 34 | $3,859 | $2,201 | 57.0% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 39 | 39 | $2,652 | $1,250 | 47.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 34 | 37 | $2,301 | $1,182 | 51.4% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 12 | 12 | $942.00 | $518.38 | 55.0% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 23 | 85 | $588.00 | $388.88 | 66.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 218 | 329 | $30,837 | $21,233 | 68.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 70 | 105 | $13,811 | $10,058 | 72.8% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2021 | 121 | 187 | $13,956 | $9,930 | 71.2% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 99 | 114 | $11,688 | $7,739 | 66.2% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 78 | 86 | $9,713 | $6,497 | 66.9% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 78 | 78 | $9,008 | $6,304 | 70.0% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 109 | 140 | $8,455 | $5,464 | 64.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 28 | 28 | $4,780 | $3,754 | 78.5% |
| 11106 | Incisional biopsy of single skin lesion | Office | 2021 | 31 | 32 | $5,009 | $3,681 | 73.5% |
| 17000 | Destruction of skin growth | Office | 2021 | 68 | 76 | $5,148 | $2,712 | 52.7% |
| 99202 | New patient outpatient visit, total time 15-29 minutes | Office | 2021 | 22 | 22 | $1,707 | $921.64 | 54.0% |
| 11103 | Tangential biopsy of additional skin lesion | Office | 2021 | 19 | 21 | $1,125 | $862.17 | 76.6% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 39 | 146 | $995.00 | $688.19 | 69.2% |
| 99211 | Established patient outpatient visit, minimal presenting problem | Office | 2021 | 29 | 31 | $790.00 | $521.71 | 66.0% |
About Dr. Adarsh Kumar, MD
Dr. Adarsh Kumar, MD is a Dermatopathology healthcare provider based in Springfield, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1063517746.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Adarsh Kumar, MD has received a total of $690.02 in payments from pharmaceutical and medical device companies, with $127.94 received in 2022. These payments were reported across 8 transactions from 6 companies. The most common payment nature is "Food and Beverage" ($690.02).
As a Medicare-enrolled provider, Kumar has provided services to 2,929 Medicare beneficiaries, totaling 3,976 services with total Medicare billing of $207,800. Data is available for 3 years (2020–2022), covering 49 distinct procedure/service records.
Practice Information
- Specialty Dermatopathology
- Other Specialties Clinical & Laboratory Dermatological Immunology, Pediatric Dermatology
- Location Springfield, IL
- Active Since 09/14/2006
- Last Updated 01/06/2023
- Taxonomy Code 207ND0900X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1063517746
Products in Payments
- EUCRISA (Drug) $138.35
- OPZELURA (Drug) $127.94
- Erivedge (Biological) $125.00
- Enbrel (Biological) $111.70
- Tremfya (Drug) $93.86
- Humira (Biological) $93.17
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.